Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK111 injection vs placebo in moderate-to-severe plaque psoriasis
CTR20230111Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of gumokimab in psoriasis, sponsored by Akeso, Inc.. Started Feb 2023; status: completed.
02
Drugs
gumokimab
03
Conditions
psoriasis
Beyond the preview
Go deeper on CTR20230111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230111.